Journal of Clinical Endocrinology & Metabolism, Vol 79, 98-105, Copyright © 1994 by Endocrine Society

ARTICLES

Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer

M Ozata, S Suzuki, T Miyamoto, RT Liu, F Fierro-Renoy and LJ DeGroot
Department of Medicine, University of Chicago, Illinois 60637.

To determine the significance of serum thyroglobulin (Tg) level in terms of presence or absence of thyroid cancer, we evaluated available serum Tg data on and off T4 therapy in 180 patients with differentiated thyroid cancer who have now been followed up to 18 yr. The presence of cancer was established by radioiodine scans, x-rays, and clinical examination. Thirty-two patients with detectable serum Tg autoantibodies were excluded from this analysis. Tg was measured by RIA with a sensitivity of 1 ng/mL. Patients who had all stages of cancer, but who had no evidence of active disease after treatment, were grouped according to operative and 131I ablative therapy. In patients with a partial thyroidectomy with or without ablation, the presence of Tg did not indicate the presence of cancer since levels were often above either a 5 ng/mL or a 10 ng/mL cutoff. The presence of residual normal thyroid tissue decreases the diagnostic value of serum Tg assay. In patients who underwent near total (NTT) or total thyroidectomy (TT) and 131I ablation, 3 of 55 (5.5%) patients had Tg greater than 5 ng/mL and 1 of 55 (1.8%) patients had Tg greater than 10 ng/mL during therapy, whereas off therapy 13 of 57 (22.8%) patients had Tg greater than 5 ng/mL and 6 of 57 (10.5%) patients had Tg levels greater than 10 ng/mL. In this group of patients, a Tg level less than 10 ng/mL during suppressive therapy indicated the absence of apparent tumor in 54 of 55 (98.2%) of patients. Whereas sensitivity of the assay was increased by withdrawal of hormone, "false positives" increased especially at lower (3-6 ng/mL) cut-off levels. No cut-off value properly categorized all patients. These data suggest, that even in patients who underwent 131I ablation and total thyroidectomy and were thought to be cured, small foci of thyroid tissue which are undetectable by standard 2 mCi 131I scans may exist and produce some Tg. However, these residual cells do not appear to cause an adverse prognosis in most patients. In patients with recurrent or continued disease, during T4 treatment, Tg levels ranged between 2-21,000 ng/mL and 5 of 11 patients had a Tg less than 5 ng/mL. Off treatment, Tg levels ranged between 6-10,700 ng/mL and 3 of 13 patients had a Tg less than 10 ng/mL. In 4 patients Tg levels were less than 10 ng/mL on treatment but greater than 10 ng/mL off therapy.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				S.-Y. Chia, M. Milas, S. K. Reddy, A. Siperstein, M. Skugor, J. Brainard, and M. K. Gupta Thyroid-Stimulating Hormone Receptor Messenger Ribonucleic Acid Measurement in Blood as a Marker for Circulating Thyroid Cancer Cells and Its Role in the Preoperative Diagnosis of Thyroid Cancer J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 468 - 475. [Abstract] [Full Text] [PDF]

				J.-D. Lin, S.-T. Chen, T.-C. Chao, C. Hsueh, and H.-F. Weng Diagnosis and Therapeutic Strategy for Papillary Thyroid Microcarcinoma Arch Surg, October 1, 2005; 140(10): 940 - 945. [Abstract] [Full Text] [PDF]

				C. Ma, A. Kuang, J. Xie, and T. Ma Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning J. Nucl. Med., September 1, 2005; 46(9): 1473 - 1480. [Abstract] [Full Text] [PDF]

				C. Ma, J. Xie, and A. Kuang Is Empiric 131I Therapy Justified for Patients with Positive Thyroglobulin and Negative 131I Whole-Body Scanning Results? J. Nucl. Med., July 1, 2005; 46(7): 1164 - 1170. [Abstract] [Full Text] [PDF]

				R. J. Robbins, S. Srivastava, A. Shaha, R. Ghossein, S. M. Larson, M. Fleisher, and R. M. Tuttle Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6010 - 6016. [Abstract] [Full Text] [PDF]

				P. Chinnappa, L. Taguba, R. Arciaga, C. Faiman, A. Siperstein, A. E. Mehta, S. K. Reddy, C. Nasr, and M. K. Gupta Detection of Thyrotropin-Receptor Messenger Ribonucleic Acid (mRNA) and Thyroglobulin mRNA Transcripts in Peripheral Blood of Patients with Thyroid Disease: Sensitive and Specific Markers for Thyroid Cancer J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3705 - 3709. [Abstract] [Full Text] [PDF]

				C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, and S. K. G. Grebe Phantoms in the Assay Tube: Heterophile Antibody Interferences in Serum Thyroglobulin Assays J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3069 - 3074. [Abstract] [Full Text] [PDF]

				D Grammatopoulos, Y Elliott, S C Smith, I Brown, R J Grieve, E W Hillhouse, M A Levine, and M D Ringel Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer Mol. Pathol., June 1, 2003; 56(3): 162 - 166. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, F. Pacini, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1433 - 1441. [Abstract] [Full Text] [PDF]

				M. K. Gupta, L. Taguba, R. Arciaga, A. Siperstein, C. Faiman, A. Mehta, and S. S. K. Reddy Detection of Circulating Thyroid Cancer Cells by Reverse Transcription-PCR for Thyroid-stimulating Hormone Receptor and Thyroglobulin: The Importance of Primer Selection Clin. Chem., October 1, 2002; 48(10): 1862 - 1865. [Full Text] [PDF]

				F. Pacini, M. Capezzone, R. Elisei, C. Ceccarelli, D. Taddei, and A. Pinchera Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1499 - 1501. [Abstract] [Full Text] [PDF]

				M K. Jones Management of papillary and follicular thyroid cancer J R Soc Med, January 7, 2002; 95(7): 325 - 326. [Full Text] [PDF]

				C. Massart and D. Maugendre Importance of the Detection Method for Thyroglobulin Antibodies for the Validity of Thyroglobulin Measurements in Sera from Patients with Graves Disease Clin. Chem., January 1, 2002; 48(1): 102 - 107. [Abstract] [Full Text] [PDF]

				A. David, A. Blotta, M. Bondanelli, R. Rossi, E. Roti, L. E. Braverman, L. Busutti, and E. C. d. Uberti Serum Thyroglobulin Concentrations and 131I Whole-Body Scan Results in Patients with Differentiated Thyroid Carcinoma After Administration of Recombinant Human Thyroid-Stimulating Hormone J. Nucl. Med., October 1, 2001; 42(10): 1470 - 1475. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				R. J. Robbins, R. M. Tuttle, R. N. Sharaf, S. M. Larson, H. K. Robbins, R. A. Ghossein, A. Smith, and W. D. Drucker Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 619 - 625. [Abstract] [Full Text]

				B. Schluter, K. H. Bohuslavizki, W. Beyer, M. Plotkin, R. Buchert, and M. Clausen Impact of FDG PET on Patients with Differentiated Thyroid Cancer Who Present with Elevated Thyroglobulin and Negative 131I Scan J. Nucl. Med., January 1, 2001; 42(1): 71 - 76. [Abstract] [Full Text] [PDF]

				Levothyroxine Suppression of Thyroglobulin in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4549 - 4553. [Abstract] [Full Text]

				R. S. Haber The Diagnosis of Recurrent Thyroid Cancer--A New Approach J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4189 - 4190. [Full Text]

				S. I. Sherman and J. Gopal Thyroglobulin Positive, RAI Negative Thyroid Cancers: The Role of Conservative Management J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4199 - 4200. [Full Text]

				M. D. Ringel, P. W. Ladenson, and M. A. Levine Molecular Diagnosis of Residual and Recurrent Thyroid Cancer by Amplification of Thyroglobulin Messenger Ribonucleic Acid in Peripheral Blood J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4435 - 4442. [Abstract] [Full Text]

				M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]

				P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri, F. Brucker-Davis, D. S. Cooper, J. R. Garber, F. E. Wondisford, T. F. Davies, L. J. DeGroot, G. H. Daniels, et al. Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma N. Engl. J. Med., September 25, 1997; 337(13): 888 - 896. [Abstract] [Full Text] [PDF]

				R. D. Utiger Follow-Up of Patients with Thyroid Carcinoma N. Engl. J. Med., September 25, 1997; 337(13): 928 - 931. [Full Text]